ITGB2 Gene Gain as a Prognostic Marker for Early Recurrence in Luminal HER2-Negative High Proliferative Breast Cancer
ITGB2 gain represents an unfavorable prognostic marker for early recurrence in luminal HER2-negative high proliferative breast cancer, with potential therapeutic implications.
Authors
- Pei‐Ju Lien (ORCID: https://orcid.org/0000-0003-4644-1533)
- Jiun‐I Lai (ORCID: https://orcid.org/0000-0002-8233-5466)
- Jen‐Hwey Chiu (ORCID: https://orcid.org/0000-0003-3046-6250)
- Ta‐Chung Chao (ORCID: https://orcid.org/0000-0003-1451-1939)
- Chih‐Yi Hsu (ORCID: https://orcid.org/0000-0002-1667-4291)
- Ling‐Ming Tseng (ORCID: https://orcid.org/0000-0002-4648-6646)
- Wan‐Lun Wang (ORCID: https://orcid.org/0000-0002-0344-7954)
- Chunyu Liu (ORCID: https://orcid.org/0000-0002-5986-4415)
- Ji‐Lin Chen (ORCID: https://orcid.org/0000-0002-9277-4083)
- Yi‐Fang Tsai (ORCID: https://orcid.org/0000-0001-7665-0462)
- Chi-Cheng Huang
Institutions
- National Yang Ming Chiao Tung University (TW)
- National Taiwan University (TW)
- Taipei Veterans General Hospital (TW)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2025-12-04
- DOI
- https://doi.org/10.4143/crt.2025.651
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Taipei Veterans General Hospital
- National Science and Technology Council